FibroGen, Inc. (NASDAQ:FGEN – Get Rating) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 4,950,000 shares, a decrease of 9.2% from the July 15th total of 5,450,000 shares. Currently, 5.8% of the company's shares are sold short. Based on an average daily volume of 971,600 shares, the short-interest ratio is presently 5.1 days.

FibroGen Stock Performance

Shares of FGEN remained flat at $14.44 during midday trading on Wednesday. 11,717 shares of the stock were exchanged, compared to its average volume of 653,054. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -6.05 and a beta of 0.87. The company's 50 day simple moving average is $11.91 and its 200 day simple moving average is $11.98. FibroGen has a 52 week low of $7.81 and a 52 week high of $16.91.

FibroGen (NASDAQ:FGEN – Get Rating) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. FibroGen had a negative return on equity of 100.51% and a negative net margin of 83.64%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same quarter in the previous year, the business earned ($1.45) earnings per share. The business's revenue was up 22.3% compared to the same quarter last year. As a group, analysts anticipate that FibroGen will post -3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On FibroGen

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on FGEN shares. Cowen boosted their price target on shares of FibroGen to $14.00 in a report on Monday. The Goldman Sachs Group lowered their target price on FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a report on Tuesday, May 24th. Finally, StockNews.com cut shares of FibroGen from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th.

FibroGen Company Profile

(Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

See Also

• Get a free copy of the StockNews.com research report on FibroGen (FGEN)
• Lowe's Stands Out Amid Q2 Retail Reports
• Agilent Technologies Proves Its Worth VS Illumina
• Target's Results Cap Upside Potential For Retail Stocks
• Are These 3 Video Game Stocks Now In Play?
• 2 Long-Term EV Plays Trading Under $20

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.